Information about Ropinirole
Ropinirole is a selective dopamine receptor agonist used in the therapy of Parkinson disease.
Liver safety of Ropinirole
Ropinirole therapy is associated with low rate of transient serum enzyme elevations during treatment and has been implicated in rare cases of acute liver injury.
Mechanism of action of Ropinirole
Ropinirole (roe pin' i role") is a synthetic, nonergot derivative dopamine receptor agonist that has selective activity for the D2 class of dopamine receptors and little agonist activity for the D1 class. For this reason, ropinirole may be better tolerated than bromocriptine or pergolide, which act on both classes of dopamine receptors.
FDA approval information for Ropinirole
Ropinirole was approved for use in the United States in 1997 for the therapy of symptomatic Parkinson disease. Indications were later expanded to include restless legs syndrome. Ropinirole is available in tablets of 0.25, 0.50, 1, 2, 3, 4 and 5 mg under the brand name of Requip. Ropinirole is typically initiated in low doses, with adjustment upwards based upon tolerance and clinical effects. In treatment of Parkinson disease, the typical dose of ropinirole is 3 to 6 mg daily in three divided doses, often but not always in combination with levodopa/carbidopa. Ropinirole can be initiated more quickly than bromocriptine or pergolide and does not cause the profound hypotension and nausea that are typical of the ergot derivatives. Rolinirole is also approved for use in restless legs syndrome, typically starting at 0.25 mg daily, 1 to 3 hours before bedtime, and increasing the dose slowly based upon tolerance and effect.
Side effects of Ropinirole
Common side effects of ropinirole include somnolence, fatigue, vivid dreams, anxiety, confusion, depression, dizziness, headache and gastrointestinal upset, symptoms that are typical of dopaminergic stimulation.